Xeljanz is the first janus kinase (JAK) inhibitor class drug approved in psoriatic arthritis ... score at three months in patients receiving Xeljanz 5 mg twice daily treatment in combination ...

so the drug missed the twin objectives of showing non-inferiority to the TNF drugs. There was also no difference between the 5mg and 10mg doses of Xeljanz tested in the trial, said Pfizer ...